These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 34448858)

  • 1. Characterization of an Anti-Ebola Virus Hyperimmune Globulin Derived From Convalescent Plasma.
    Ciencewicki JM; Herbert AS; Storm N; Josleyn NM; Huie KE; McKay LGA; Griffiths A; Dye JM; Willis T; Arora V
    J Infect Dis; 2022 Feb; 225(4):733-740. PubMed ID: 34448858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.
    Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R
    Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.
    Dean CL; Hooper JW; Dye JM; Zak SE; Koepsell SA; Corash L; Benjamin RJ; Kwilas S; Bonds S; Winkler AM; Kraft CS
    Transfusion; 2020 May; 60(5):1024-1031. PubMed ID: 32129478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Ebola Virus Antibody Levels in Convalescent Plasma and Viral Load After Plasma Infusion in Patients With Ebola Virus Disease.
    Brown JF; Dye JM; Tozay S; Jeh-Mulbah G; Wohl DA; Fischer WA; Cunningham CK; Rowe K; Zacharias P; van Hasselt J; Norwood DA; Thielman NM; Zak SE; Hoover DL
    J Infect Dis; 2018 Jul; 218(4):555-562. PubMed ID: 29659889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the therapeutic effect of antibodies targeting the Ebola glycoprotein using a novel BSL2-compliant rVSVΔG-EBOV-GP infection model.
    Lee HN; McWilliams IL; Lewkowicz AP; Engel K; Ireland DDC; Kelley-Baker L; Thacker S; Piccardo P; Manangeeswaran M; Verthelyi D
    Emerg Microbes Infect; 2021 Dec; 10(1):2076-2089. PubMed ID: 34674613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of Potent Fully Human Polyclonal Antibodies against Ebola Zaire Virus in Transchromosomal Cattle.
    Dye JM; Wu H; Hooper JW; Khurana S; Kuehne AI; Coyle EM; Ortiz RA; Fuentes S; Herbert AS; Golding H; Bakken RA; Brannan JM; Kwilas SA; Sullivan EJ; Luke TC; Smith G; Glenn G; Li W; Ye L; Yang C; Compans RW; Tripp RA; Jiao JA
    Sci Rep; 2016 Apr; 6():24897. PubMed ID: 27109916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.
    Mellors J; Tipton T; Fehling SK; Akoi Bore J; Koundouno FR; Hall Y; Hudson J; Alexander F; Longet S; Taylor S; Gorringe A; Magassouba N; Konde MK; Hiscox J; Strecker T; Carroll M
    Front Immunol; 2022; 13():857481. PubMed ID: 35493467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Vesicular Stomatitis Virus-Ebola Virus Postexposure Treatment in Rhesus Macaques Infected With Ebola Virus Makona.
    Marzi A; Hanley PW; Haddock E; Martellaro C; Kobinger G; Feldmann H
    J Infect Dis; 2016 Oct; 214(suppl 3):S360-S366. PubMed ID: 27496978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgY antibodies against Ebola virus possess post-exposure protection in a murine pseudovirus challenge model and excellent thermostability.
    Zhang Y; Wei Y; Li Y; Wang X; Liu Y; Tian D; Jia X; Gong R; Liu W; Yang L
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0008403. PubMed ID: 33711011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 11. Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus.
    Macneil A; Reed Z; Rollin PE
    PLoS Negl Trop Dis; 2011 Jun; 5(6):e1175. PubMed ID: 21666792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents.
    Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X
    Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.
    Bounds CE; Kwilas SA; Kuehne AI; Brannan JM; Bakken RR; Dye JM; Hooper JW; Dupuy LC; Ellefsen B; Hannaman D; Wu H; Jiao JA; Sullivan EJ; Schmaljohn CS
    PLoS One; 2015; 10(9):e0137786. PubMed ID: 26422247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant vesicular stomatitis virus expressing Ebola virus glycoprotein (rVSV-EBOV), a new Ebola vaccine.
    Kasereka MC; Mumtaz Z; Hawkes MT
    Drugs Today (Barc); 2021 Jan; 57(1):27-45. PubMed ID: 33594388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice.
    Bengtsson KL; Song H; Stertman L; Liu Y; Flyer DC; Massare MJ; Xu RH; Zhou B; Lu H; Kwilas SA; Hahn TJ; Kpamegan E; Hooper J; Carrion R; Glenn G; Smith G
    Vaccine; 2016 Apr; 34(16):1927-35. PubMed ID: 26921779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Dose Treatment With Vesicular Stomatitis Virus-Based Ebola Virus Vaccine Expressing Ebola Virus-Specific Artificial Micro-RNA Does Not Protect Mice From Lethal Disease.
    O'Donnell KL; Callison J; Feldmann H; Hoenen T; Marzi A
    J Infect Dis; 2023 Nov; 228(Suppl 7):S677-S681. PubMed ID: 37186162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2.
    Racine T; Denizot M; Pannetier D; Nguyen L; Pasquier A; Raoul H; Saluzzo JF; Kobinger G; Veas F; Herbreteau CH
    J Infect Dis; 2019 Jun; 220(1):41-45. PubMed ID: 30852585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.
    Zhang X; Zhang T; Davis JN; Marzi A; Marchese AM; Robek MD; van den Pol AN
    J Virol; 2020 Mar; 94(8):. PubMed ID: 32051271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.
    Bushmaker T; Feldmann F; Lovaglio J; Saturday G; Griffin AJ; O'Donnell KL; Strong JE; Sprecher A; Kobinger G; Geisbert TW; Marzi A; Feldmann H
    J Infect Dis; 2023 Nov; 228(Suppl 7):S721-S729. PubMed ID: 37474155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.